Current Status of BTKi Treatment for CLL/SLL in China
ConditionCLL/SLL
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorThe First Affiliated Hospital with Nanjing Medical University
About this trial
BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.
Eligibility criteria
Qualifiers
Age ≥ 18 years;
Patients with a confirmed diagnosis of CLL/SLL;
Received BTK inhibitor treatment between February 2023 and February 2024.
Disqualifiers
Patients with other types of lymphoma;
Cases deemed unsuitable for inclusion in this study by the investigators.
Trial design
Treatments tested in this trial
- BTK inhibitor
Treatment groups
1,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov